These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1210 related articles for article (PubMed ID: 19686695)

  • 1. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens.
    Li C; Ping J; Jing B; Deng G; Jiang Y; Li Y; Tian G; Yu K; Bu Z; Chen H
    Biochem Biophys Res Commun; 2008 Jul; 372(2):293-7. PubMed ID: 18501701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus.
    Swayne DE; Lee CW; Spackman E
    Avian Pathol; 2006 Apr; 35(2):141-6. PubMed ID: 16595307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype.
    Pavlova SP; Veits J; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Aug; 27(37):5085-90. PubMed ID: 19573638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
    Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
    Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
    Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
    Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M; Pritchard N; Swayne DE; Selleck P; Karaca K; Suarez DL; Audonnet JC; Mickle TR
    Ann N Y Acad Sci; 2006 Oct; 1081():193-201. PubMed ID: 17135511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype.
    Peeters B; de Boer SM; Tjeerdsma G; Moormann R; Koch G
    Vaccine; 2012 Nov; 30(49):7078-83. PubMed ID: 23036502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.
    Lee CW; Senne DA; Suarez DL
    Vaccine; 2004 Aug; 22(23-24):3175-81. PubMed ID: 15297071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
    Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
    Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
    Jiang Y; Yu K; Zhang H; Zhang P; Li C; Tian G; Li Y; Wang X; Ge J; Bu Z; Chen H
    Antiviral Res; 2007 Sep; 75(3):234-41. PubMed ID: 17451817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks.
    Middleton D; Bingham J; Selleck P; Lowther S; Gleeson L; Lehrbach P; Robinson S; Rodenberg J; Kumar M; Andrew M
    Virology; 2007 Mar; 359(1):66-71. PubMed ID: 17028058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.
    Swayne DE; Suarez DL; Spackman E; Jadhao S; Dauphin G; Kim-Torchetti M; McGrane J; Weaver J; Daniels P; Wong F; Selleck P; Wiyono A; Indriani R; Yupiana Y; Sawitri Siregar E; Prajitno T; Smith D; Fouchier R
    J Virol; 2015 Apr; 89(7):3746-62. PubMed ID: 25609805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.